☰
DUNYA NEWS
Live
✕

Pakistan makes barcode, serialisation mandatory for all medicines

Updated on:

Pakistan introduces mandatory 2D barcodes on medicine packs under new rules

ISLAMABAD (Dunya News) – The Drug Regulatory Authority of Pakistan (DRAP) has made barcoding and serialisation mandatory for medicines under new regulations aimed at strengthening the tracking and monitoring of pharmaceutical products across the country.

According to DRAP, all medicines manufactured from October 9, 2026, onwards must carry a 2D barcode on their packaging. The authority has directed local pharmaceutical manufacturers and importers to ensure full compliance with the new requirements.

Under the regulations, medicine packaging must carry essential identification details, including the manufacturing date, expiry date, batch number, retail price and a unique serial number.

The move is intended to improve the traceability of medicines and ensure that product information can be verified throughout the supply chain.

Digital tracking requirements

DRAP has also made it mandatory for information submitted to the Track and Trace System to match exactly with the details printed on the original medicine packaging.

Any discrepancy between digital records and packaging information, including incorrect reporting, inaccurate data or unauthorised alterations, will be treated as a violation of the regulations.

The authority has directed pharmaceutical companies and importers to ensure the accuracy and consistency of all information entered into the system.

Inspections and legal action

To monitor compliance, DRAP inspectors will conduct inspections at pharmaceutical manufacturing facilities, importers' premises and supply chain centres.

During these inspections, officials will examine different medicine batches and verify the information recorded in the Track and Trace System against the details available on product packaging.

DRAP has warned that companies found violating the new requirements, submitting incorrect information or tampering with product records will face legal action under the DRAP Act and the Drugs Act.

Existing stocks exempt

The authority has clarified that medicines manufactured before October 9, 2026, will remain exempt from the new barcoding and serialisation requirements.

Existing stocks produced before the implementation date will be allowed to remain on sale until exhausted, meaning pharmaceutical companies and distributors can continue selling these products without applying the new requirements retrospectively.

Recommended For You

Follow Us on Social Media